Syndax Pharmaceuticals (SNDX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow

Syndax 珍 | --- | --- | |-------|--------------------------| | | Dose: 1mg/kg q2wk | | | n= 23 patients | | | Primary endpoint: ORR* | | | (2014 NIH GVHD criteria) | KPS at enrollment, median (range) 80 (60, 100) 80 (60, 90) 80 (60, 100) • No evidence of end-organ damage, myositis/pancreatitis with enzyme elevations 52% FIBROSIS CSF-1R Circulating Monocyte CSF-1 Circulating Monocyte Macrophage Tissue Fibroblasts Collagen CSF-1R CSF-1R CSF-1 Circulating Monocyte Blood vessel CSF-1R M2 macrophage 17 Myeloablat ...